Replies to post #78307 on Biotech Values

[mcbio]

Re: MNTA/FDA Assistance

When the FDA needed help last year to figure out the contamination problem with Chinese heparin, the FDA turned to MNTA, not Teva (#msg-28748329).

I think this is a major point that really can't be emphasized enough. And it's one of the main reasons I decided to invest in MNTA. The fact that they were able to assist the FDA and identify the contaminated heparin can only help in giving the FDA reassurances with respect to MNTA's technology. That should give MNTA a clear leg up on the competition.

[randychub]

"Teva has what it takes to fully characterize Lovenox to the FDA’s satisfaction. When the FDA needed help last year to figure out the contamination problem with Chinese heparin, the FDA turned to MNTA, not Teva"

If TEVA's drug is not a fully characterized Lovenox, could MNTA's technology be used to prove it?

R